COVID-19: Information on ASPIRA LABS Operations

Click to Learn More
  • Home
  • Recent News and Upcoming Events

Recent News and Upcoming Events

Recent News


  • ASPiRA LABS’ OVA1 Technology Receives “Level B” Recommendation in the Latest ACOG Clinical Management Guidelines for the Management of Adnexal Masses

      AUSTIN, Texas — ASPiRA LABS, a Vermillion company (NASDAQ: VRML), today announced the inclusion of the OVA1 /“Multivariate Index Assay” in The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin Number 174, dated November 2016. This bulletin outlines ACOG’s “new” clinical management guidelines for adnexal mass management. These new clinical management guidelines replace…

  • Vermillion to Report Third Quarter 2016 Financial Results and Host Investor Conference Call on November 10th

      AUSTIN, Texas — Vermillion, Inc. ((NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its third quarter financial results on Thursday, November 10, 2016, followed by an investor conference call and webcast at 4:30 p.m. (ET). Thursday, November 10th @ 4:30 p.m. (ET)  Domestic: 1-888-296-4197 International: 1-719-325-2462 Conference…

  • Vermillion CEO to Present at Women in Bio – New York

      AUSTIN, Texas — Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that CEO, Valerie Palmieri, will present at the Women in Bio – New York Chapter meeting at the PRIDE Global Event Space in New York, NY on October 20, 2016 at 6:00PM EST. The presentation, titled “Ovarian Cancer:…

  • ASPiRA LABs OVA1® Test Now Covered By CareFirst BlueCross BlueShield

      AUSTIN, Texas — ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced a major contract agreement with CareFirst BlueCross BlueShield for their U.S. FDA cleared ovarian cancer risk assessment test, OVA1. CareFirst serves over three million patients throughout Maryland and Washington, D.C., and Virginia and the area has the greatest population density in the…

  • Vermillion and ASPiRA LABs Applaud the FDA's Position on Ovarian Cancer Screening

      AUSTIN, Texas — ASPiRA LABs,  a Vermillion company (NASDAQ:VRML), today announced its support for the recent US Food and Drug Administration (FDA) safety communication which recommends against the use of any screening tests for ovarian cancer. Earlier this week, the FDA announced  that it is alerting women about the risks associated with the use…

Upcoming Events


  • March 15–17, 2020

    Laguna Niguel, CA

    32nd Annual Roth Conference

  • March 28–31, 2020

    Toronto, Canada

    Society of Gynecologic Oncology Annual Meeting

  • March 28 - April 3

    La Jolla, CA

    ACOOG 87th Annual Conference

  • April 24–27, 2020

    Seattle, WA

    American College of Obstetricians and Gynecologists Annual Meeting

Investor Relations


  • Ashley R. Robinson

    LifeSci Advisors, LLC

    617-535-7742